SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-040727
Filing Date
2024-02-21
Accepted
2024-02-21 07:47:00
Documents
16
Period of Report
2024-02-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d742672d8k.htm   iXBRL 8-K 23296
2 EX-99.1 d742672dex991.htm EX-99.1 231716
6 GRAPHIC g742672g0221045129516.jpg GRAPHIC 5520
  Complete submission text file 0001193125-24-040727.txt   410790

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgen-20240221.xsd EX-101.SCH 2865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgen-20240221_lab.xml EX-101.LAB 18757
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgen-20240221_pre.xml EX-101.PRE 11720
18 EXTRACTED XBRL INSTANCE DOCUMENT d742672d8k_htm.xml XML 3793
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

IRS No.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-14656 | Film No.: 24656407
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)